PrashantKumar Khirsariya, Ph.D., M.Sc.

2022

• 白血病、リンパ腫および固形腫瘍の治療に使用するための４－（１Ｈ－イミダゾール－５－イル）－１Ｈ－ピロロ［２，３－ｂ］ピリジン

  BRYJA Vítězslav JANOVSKÁ Pavlína GREGOROVÁ Michaela NĚMEC Václav KHIRSARIYA PrashantKumar PARUCH Kamil

  Patent

  Publisher: Japan Patent Office, state: Japan, patent's number: JP7008967, year: 2022

2021

• 4—(1h— imidazol— 5— yl) -1h-pyrrolo (2, 3-b) pyridines for use in the treatment of leukaemias, lymphomas and solid tumors

  BRYJA Vítězslav JANOVSKÁ Pavlína GREGOROVÁ Michaela NĚMEC Václav KHIRSARIYA PrashantKumar PARUCH Kamil

  Patent

  Publisher: The Australian Patents Register, state: Australia, patent's number: AU 2019246220, year: 2021

• Cytoprotective activities of kinetin purine isosteres

  MAKOVÁ Barbara MIK Václav LIŠKOVÁ Barbora GONZALEZ Gabriel VÍTEK Dominik MEDVEDÍKOVÁ Martina MONFORT Beata RUČILOVÁ Veronika KADLECOVÁ Alena KHIRSARIYA Prashant BARREIRO Zoila Gándara HAVLÍČEK Libor ZATLOUKAL Marek SOURAL Miroslav PARUCH Kamil D'AUTRÉAUX Benoit HAJDÚCH Marián STRNAD Miroslav VOLLER Jiří

  Article in Periodical

  Bioorganic and Medicinal Chemistry, year: 2021, volume: 33, edition: March, DOI

2020

• The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe

  DRÁPELA Stanislav KHIRSARIYA PrashantKumar VAN WEERDEN Wytske M FEDR Radek SUCHÁNKOVÁ Tereza BÍZOVA Diana ČERVENÝ Jan HAMPL Aleš PUHR Martin WATSON William R CULIG Zoran KREJČÍ Lumír PARUCH Kamil SOUČEK Karel

  Article in Periodical

  Molecular oncology, year: 2020, volume: 14, edition: 10, DOI

2019

• ATR-CHK1 signaling is active and targetable in quiescent CLL cells

  BOUDNÝ Miroslav KHIRSARIYA PrashantKumar BORSKÝ Marek BRYCHTOVÁ Yvona PARUCH Kamil TRBUŠEK Martin

  Conference abstract

  Year: 2019, type: Conference abstract

• CDK12 controls G1/S progression by regulating RNAPII processivity at core DNA replication genes

  CHIRACKAL MANAVALAN Anil Paul PILAŘOVÁ Květa KLUGE Michael BARTHOLOMEEUSEN Koen RÁJECKÝ Michal OPPELT Jan KHIRSARIYA PrashantKumar PARUCH Kamil KREJČÍ Lumír FRIEDEL Caroline C BLAŽEK Dalibor

  Article in Periodical

  EMBO reports, year: 2019, volume: 20, edition: 9, DOI

• Cílená inhibice kasein kinázy 1 v léčbě chronické lymfoidní leukémie.

  JANOVSKÁ Pavlína GREGOROVÁ M. NĚMEC Václav KHIRSARIYA PrashantKumar VERNER Jan KOHOUTEK J. POPPOVÁ Lucie PAVLOVÁ Šárka PLEVOVÁ Karla POSPÍŠILOVÁ Šárka PARUCH Kamil BRYJA Vítězslav

  Conference abstract

  Year: 2019, type: Conference abstract

• Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells

  BOUDNÝ Miroslav ZEMANOVÁ Jana KHIRSARIYA PrashantKumar BORSKÝ Marek VERNER Jan ČERNÁ Jana OLTOVÁ Alexandra ŠEDA Václav MRÁZ Marek JAROŠ Josef JAŠKOVÁ Zuzana ŠPUNAROVÁ Michaela BRYCHTOVÁ Yvona SOUČEK Karel DRÁPELA Stanislav KAŠPÁRKOVÁ Marie MAYER Jiří PARUCH Kamil TRBUŠEK Martin

  Article in Periodical

  Haematologica, year: 2019, volume: 104, edition: 12, DOI

• Potenciál inhibice proteinu checkpoint kinase 1 u chronické lymfocytární leukémie s mutacemi v genu TP53.

  BOUDNY´ Miroslav ZEMANOVA´ Jana KHIRSARIYA PrashantKumar BORSKÝ Marek VERNER Jan ČERNÁ Jana ŠEDA Václav MRÁZ Marek OLTOVÁ Alexandra JAROŠ J. JAŠKOVÁ Zuzana ŠPUNAROVÁ Michaela BRYCHTOVÁ Yvona MAYER Jiří PARUCH Kamil TRBUŠEK Martin

  Conference abstract

  Year: 2019, type: Conference abstract

2018

• CDK12 kinase activity controls G1/S progression by regulating optimal transcription of core DNA replication genes

  CHIRACKAL MANAVALAN Anil Paul PILAŘOVÁ Květa KLUGE M. BARTHOLOMEEUSEN Koen OPPELT Jan KHIRSARIYA PrashantKumar PARUCH Kamil KREJČÍ Lumír FRIEDEL C. BLAŽEK Dalibor

  Conference abstract

  Year: 2018, type: Conference abstract